Understand the acquired resistance of RTK inhibitors by computational receptor tyrosine kinases network.

作者: Yuanxin Tian , Yunci Ma , Shaoyu Wu , Tingting Zhang , Zhonghuang Li

DOI: 10.1016/J.COMPBIOLCHEM.2018.07.017

关键词: Computational biologyPI3K/AKT/mTOR pathwayBiologyReceptor tyrosine kinase inhibitorDrug resistanceReceptor tyrosine kinaseCrosstalk (biology)Acquired resistanceProtein–protein interactionRap1

摘要: Abstract Receptor Tyrosine Kinase inhibitors are the most popular anti-cancer drug types. But resistance is major challenge. Our study on network with 1334 proteins and their 2623 interactions which retrieved from 52 RTKs indicated that were key controllers of protein-protein network. Direct or indirect (shortest path 2) often associated to in literature. The results based KEGG pathway analysis demonstrated Rap1 signal would also contribute inhibitor as well known Ras PI3K/Akt pathway. pathways can crosstalk within between complex signals transduction networks, then activate upstream downstream pathway, and/or other oncogenes, lead acquired resistance. gave a systematically global view understand provided clue how combine different targets for synergy targeted inhibitors.

参考文章(50)
Oriol Arqués, Irene Chicote, Isabel Puig, Stephan P Tenbaum, Guillem Argilés, Rodrigo Dienstmann, Natalia Fernandez, Ginevra Caratu, Judit Matito, Daniel Silberschmidt, Jordi Rodon, Stefania Landolfi, Aleix Prat, Eloy Espin, Ramon Charco, Paolo Nuciforo, Ana Vivancos, Wenlin Shao, Josep Tabernero, Hector G Palmer, None, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer Clinical Cancer Research. ,vol. 22, pp. 644- 656 ,(2016) , 10.1158/1078-0432.CCR-14-3081
Andy J Chien, Randall T Moon, WNTS and WNT receptors as therapeutic tools and targets in human disease processes Frontiers in Bioscience. ,vol. 12, pp. 448- 457 ,(2007) , 10.2741/2074
Isabel Heidegger, Johann Kern, Philipp Ofer, Helmut Klocker, Petra Massoner, Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis Oncotarget. ,vol. 5, pp. 2723- 2735 ,(2014) , 10.18632/ONCOTARGET.1884
Fumiaki Ito, None, Foreword. Target therapy for cancer: anti-cancer drugs targeting growth-factor signaling molecules. Biological & Pharmaceutical Bulletin. ,vol. 34, pp. 1773- 1773 ,(2011) , 10.1248/BPB.34.1773
Yun Xie, Zong Dai, Xiao-Yong Zou, Zhan-Chao Li, Yan-Hua Lai, Li-Li Chen, Identifying and prioritizing disease-related genes based on the network topological features. Biochimica et Biophysica Acta. ,vol. 1844, pp. 2214- 2221 ,(2014) , 10.1016/J.BBAPAP.2014.08.009
Norihiro Yamaguchi, Antonio R. Lucena-Araujo, Sohei Nakayama, Lorena L. de Figueiredo-Pontes, David A. Gonzalez, Hiroyuki Yasuda, Susumu Kobayashi, Daniel B. Costa, Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer. ,vol. 83, pp. 37- 43 ,(2014) , 10.1016/J.LUNGCAN.2013.09.019
Niels Reinmuth, Sebastian Kloos, Arne Warth, Angela Risch, Thomas Muley, Hans Hoffmann, Michael Thomas, Michael Meister, Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. Human Pathology. ,vol. 45, pp. 1162- 1168 ,(2014) , 10.1016/J.HUMPATH.2014.01.010
Chao Huang, Chunli Zheng, Yan Li, Yonghua Wang, Aiping Lu, Ling Yang, Systems pharmacology in drug discovery and therapeutic insight for herbal medicines Briefings in Bioinformatics. ,vol. 15, pp. 710- 733 ,(2014) , 10.1093/BIB/BBT035
Kathryn E. Ware, Marianne E. Marshall, Lydia R. Heasley, Lindsay Marek, Trista K. Hinz, Paula Hercule, Barbara A. Helfrich, Robert C. Doebele, Lynn E. Heasley, Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression PLoS ONE. ,vol. 5, pp. e14117- ,(2010) , 10.1371/JOURNAL.PONE.0014117